Soluble form of a receptor for advanced glycation end products (sRAGE) as a biomarker

Frontiers in Bioscience - Elite

Volumn 2 E, Issue 4, 2010, Pages 1184-1195

  Yamagishi, Sho Ichi ^a   Matsui, Takanori ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

AGEs; Biomarker; Oxidative stress; RAGE; Review

Indexed keywords

ADVANCED GLYCOSYLATION END PRODUCT RECEPTOR; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; BIOLOGICAL MARKER; IMMUNOGLOBULIN RECEPTOR;

CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; DEGENERATIVE DISEASE; DIABETES MELLITUS; HUMAN; HYPERTENSION; INFLAMMATION; METABOLISM; REVIEW;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; HUMANS; HYPERTENSION; INFLAMMATION; KIDNEY FAILURE, CHRONIC; NEURODEGENERATIVE DISEASES; RECEPTORS, IMMUNOLOGIC;

EID: 77957345420     PISSN: 19450494     EISSN: 19450508     Source Type: Journal    
DOI: 10.2741/e178     Document Type: Article

References (117)

1. M. Takeuchi and S. Yamagishi: Involvement of toxic AGEs (TAGE) in the pathogenesis of diabetic vascular complications and Alzheimer's disease. J Alzheimers Dis 16, 845-858 (2009)
2. M. A. Glomb and V. M. Monnier: Mechanism of protein modification by glyoxal and glycoaldehyde, reactive intermediates of the Maillard reaction. J Biol Chem 70, 10017-26 (1995)
3. R. Bucala and A. Cerami: Advanced glycosylation: chemistry, biology, and implications for diabetes and aging. Adv Pharmacol 23, 1-34 (1992)
4. H. Vlassara, R. Bucala and L. Striker: Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Lab Invest 70, 138-151 (1994) (Pubitemid 24090096)
5. Brownlee M. Advanced protein glycosylation in diabetes and aging. Ann Rev Med 1995;46:223-34.
6. S. Yamagishi and T. Imaizumi: Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des 11, 2279-2299 (2005) (Pubitemid 40872698)
7. S. Rahbar and J. L. Figarola: Novel inhibitors of advanced glycation endproducts. Arch Biochem Biophys 419, 63-79 (2003) (Pubitemid 37287559)
8. A. Bierhaus, M. A. Hofmann, R. Ziegler and P. P. Nawroth: AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. Cardiovasc Res 37, 586-600 (1998) (Pubitemid 28231153)
9. A. M. Schmidt and D. Stern: Atherosclerosis and diabetes: the RAGE connection. Curr Atheroscler Rep 2, 430-436 (2000)
10. M. Takeuchi and S. Yamagishi: Possible involvement of advanced glycation end-products (AGEs) in the pathogenesis of Alzheimer's disease. Curr Pharm Des 14, 973-978 (2008) (Pubitemid 351753285)
11. R. Abe and S. Yamagishi: AGE-RAGE system and carcinogenesis. Curr Pharm Des 14, 940-945 (2008) (Pubitemid 351753280)
12. S. Yamagishi, S. Ueda and S. Okuda: Food-derived advanced glycation end products: a novel therapeutic target for various disorders. Curr Pharm Des 13, 2832-2836 (2007) (Pubitemid 350130976)
13. S. Yamagishi, K. Nakamura and T. Matsui: Regulation of advanced glycation end product (AGE)-receptor (RAGE) system by PPAR-gamma agonists and its implication in cardiovascular disease. Pharm Res 60, 174-178 (2009)
14. H. L. Nienhuis, J. Westra, A. J. Smit, P. C. Limburg, C. G. Kallenberg and M. Bijl: AGE and their receptor RAGE in systemic autoimmune disease: an inflammation propagating factor contributing to accelerated atherosclerosis. Autoimmunity 42, 302-304 (2009)
15. L. Park, K. G. Raman, K. J. Lee, Y. Lu, L. J. Jr. Ferran, W. S. Chow, D. Stern and A. M. Schmidt: Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 4, 1025-1031 (1998) (Pubitemid 28417334)
16. L. G. Bucciarelli, T. Wendt, W. Qu, Y. Lu, E. Lalla, L. L. Rong, M. T. Goova, B. Moser, T. Kislinger, D. C. Lee, Y. Kashyap, D. M. Stern and A. M. Schmidt: RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 106, 2827-2835 (2002) (Pubitemid 35396983)
17. G. R. Barile, S. I. Pachydaki, S. R. Tari, S. E. Lee, C. M. Donmoyer, W. Ma, L. L. Rong, L. G. Buciarelli, T. Wendt, H. Horig, B. I. Hudson, W. Qu, A. D. Weinberg. S. F. Yan and A. M. Schmidt: The RAGE axis in early diabetic retinopathy. Invest Ophthalmol Vis Sci 46, 2916-2924 (2005) (Pubitemid 43086714)
18. Y. Kaji, T. Usui, S. Ishida, K. Yamashiro, J. Moore, Y. Yamamoto, H. Yamamoto and A. P. Adamis: Inhibition of diabetic leukostasis and blood-retinal barrier breakdown with a soluble form of a receptor for advanced glycation end products. Invest Ophthalmol Vis Sci 48, 858-865 (2007) (Pubitemid 351260723)
19. S. F. Yan, V. D'Agati, A. M. Schmidt and R. Ramasamy R: Receptor for Advanced Glycation Endproducts (RAGE): a formidable force in the pathogenesis of the cardiovascular complications of diabetes & aging. Curr Mol Med 7, 699-710 (2007)
20. B. Moser, B. I. Hudson and A. M. Schmidt: Soluble RAGE: a hot new biomarker for the hot joint? Arthritis Res Ther 7, 142-144 (2005) (Pubitemid 40936603)
21. B. I. Hudson, E. Harja, B. Moser and A. M. Schmidt: Soluble levels of receptor for advanced glycation endproducts (sRAGE) and coronary artery disease: the next C-reactive protein? Arterioscler Thromb Vasc Biol 25, 879-882 (2005) (Pubitemid 40637200)
22. L. E. Hanford, J. J. Enghild, Z. Valnickova, S. V. Petersen, L. M. Schaefer, T. M. Schaefer, T. A. Reinhart and T. D. Oury: Purification and characterization of mouse soluble receptor for advanced glycation end products (sRAGE). J Biol Chem 279, 50019-50024 (2004) (Pubitemid 39577812)
23. H. Yonekura, Y. Yamamoto, S. Sakurai, R. G. Petrova, M. J. Abedin, H. Li, K. Yasui, M. Takeuchi, Z. Makita, S. Takasawa, H. Okamoto, T. Watanabe and H. Yamamoto: Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 370, 1097-1109 (2003) (Pubitemid 36399105)
24. S. Yamagishi and T. Imaizumi: Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) may reflect tissue RAGE expression in diabetes. Arterioscler Thromb Vasc Biol 27, e32 (2007) (Pubitemid 46809443)
25. K. Nakamura, S. Yamagishi, Y. Nakamura, K. Takenaka, T. Matsui, Y. Jinnouchi and T. Imaizumi: Telmisartan inhibits expression of a receptor for advanced glycation end products (RAGE) in angiotensin-II-exposed endothelial cells and decreases serum levels of soluble RAGE in patients with essential hypertension. Microvasc Res 70, 137-141 (2005) (Pubitemid 41586467)
26. A. Raucci, S. Cugusi, A. Antonelli, S. M. Barabino, L. Monti, A. Bierhaus, K. Reiss, P. Saftig and M. E. Bianchi: A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J 22, 3716-3727 (2008)
27. H. Maillard-Lefebvre, E. Boulanger, M. Daroux, C. Gaxatte, B. I. Hudson and M. Lambert: Soluble receptor for advanced glycation end products: a new biomarker in diagnosis and prognosis of chronic inflammatory diseases. Rheumatology (Oxford) 48, 1190-1196 (2009)
28. F. Santilli, N. Vazzana, L. G. Bucciarelli and G. Davì: Soluble forms of RAGE in human diseases: clinical and therapeutical implications. Curr Med Chem 16, 940-952 (2009)
29. S. Yamagishi, T. Matsui T and K. Nakamura: Kinetics, role and therapeutic implications of endogenous soluble form of receptor for advanced glycation end products (sRAGE) in diabetes. Curr Drug Targets 8, 1138-1143 (2007) (Pubitemid 47578142)
30. D. Geroldi, C. Falcone and E. Emanuele: Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target. Curr Med Chem 13, 1971-1978 (2003)
31. M. Brownlee: Biochemistry and molecular cell biology of diabetic complications. Nature 414, 813-820 (2001) (Pubitemid 34000785)
32. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group: Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 342, 381-389 (2000)
33. Writing Team For The Diabetes Control And Complications Trial/Epidemiology Of Diabetes Interventions And Complications Research Group: Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 290, 2159-2167 (2003)
34. D. M. Nathan, P. A. Cleary, J. Y. Backlund, S. M. Genuth, J. M. Lachin, T. J. Orchard TJ, P. Raskin and B. Zinman; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group: Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353, 2643-2653 (2005) (Pubitemid 41817713)
35. R. R. Holman, S. K. Paul, M. A. Bethel, D. R. Matthews and H. A. Neil: 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359, 1577-1589 (2008)
36. N. Tanaka, H. Yonekura, S. Yamagishi, H. Fujimori, Y. Yamamoto and H. Yamamoto: The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factor-kappa B, and by 17beta-estradiol through Sp-1 in human vascular endothelial cells. J Biol Chem 275, 25781-25790 (2000)
37. S. Yamagishi, S. Amano, Y. Inagaki, T. Okamoto, M. Takeuchi and Z. Makita: Beraprost sodium, a prostaglandin I2 analogue, protects against advanced gycation end products-induced injury in cultured retinal pericytes. Mol Med 8, 546-550 (2002) (Pubitemid 36332366)
38. A. Bierhaus, S. Schiekofer, M. Schwaninger, M. Andrassy, P. M. Humpert, J. Chen, M. Hong, T. Luther, T. Henle, I. Klöting, M. Morcos, M. Hofmann, H. Tritschler, B. Weigle, M. Kasper, M. Smith, G. Perry, A. M. Schmidt, D. M. Stern, H. U. Häring, E. Schleicher and P. P. Nawroth: Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes 50, 2792-2808 (2001) (Pubitemid 33733131)
39. M. Challier, S. Jacqueminet, O. Benabdesselam, A. Grimaldi and J. L. Beaudeux: Increased serum concentrations of soluble receptor for advanced glycation endproducts in patients with type 1 diabetes. Clin Chem 51, 1749-1750 (2005) (Pubitemid 41233122)
40. A. Dettoraki, A. P. Gil and B. E. Spiliotis: Association between serum levels of the soluble receptor (sRAGE) for advanced glycation endproducts (AGEs) and their receptor (RAGE) in peripheral blood mononuclear cells of children with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 22, 895-904 (2009)
41. K. Nakamura, S. Yamagishi, H. Adachi, Y. Kurita-Nakamura, T. Matsui, T. Yoshida, A. Sato and T. Imaizumi: Elevation of soluble form of receptor for advanced glycation end products (sRAGE) in diabetic subjects with coronary artery disease. Diabetes Metab Res Rev 23, 368-371 (2007) (Pubitemid 47091239)
42. K. C. Tan, S. W. Shiu, W. S. Chow, L. Leng, R. Bucala and D. J. Betteridge: Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes. Diabetologia 49, 2756-2762 (2006)
43. K. Nakamura, S. Yamagishi, T. Matsui, H. Adachi, M. Takeuchi and T. Imaizumi: Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are correlated with AGEs in both diabetic and non-diabetic subjects. Clin Exp Med 7, 188-190 (2007)
44. S. Yamagishi, H. Adachi, K. Nakamura, T. Matsui, Y. Jinnouchi, K. Takenaka, M. Takeuchi, M. Enomoto, K. Furuki, A. Hino, Y. Shigeto and T. Imaizumi: Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects. Metabolism 55, 1227-1231 (2006) (Pubitemid 44215942)
45. M. Steiner, K. M. Reinhardt, B. Krammer, B. Ernst and A. D. Blann: Increased levels of soluble adhesion molecules in type 2 (non-insulin dependent) diabetes mellitus are independent of glycaemic control. Thromb Haemost 72, 979-984 (1994)
46. F. Cipollone, A. Iezzi, M. Fazia, M. Zucchelli, B. Pini, C. Cuccurullo, D. de Cesare, G. de Blasis, R. Muraro, R. Bei, F. Chiarelli, A. M. Schmidt, F. Cuccurullo, and A. Mezzetti: The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control. Circulation 108, 1070-1077 (2003) (Pubitemid 37071516)
47. N. Tanji, G. S. Markowitz, C. Fu, T. Kislinger, A. Taguchi, M. Pischetsrieder, D. Stern, A. M. Schmidt and V. D. D'Agati: Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J Am Soc Nephrol 11, 1656-1666 (2000)
48. S. I. Pachydaki, S. R. Tari, S. E. Lee, W. Ma, J. J. Tseng, A. A. Sosunov, G. Cataldergirmen, N. Scarmeas, C. Caspersen, S. Chang, W. M. Schiff, A. M. Schmidt and G. R. Barile: Upregulation of RAGE and its ligands in proliferative retinal disease. Exp Eye Res 82, 807-815 (2006) (Pubitemid 43170881)
49. P. M. Humpert, Z. Djuric, S. Kopf, G. Rudofsky, M. Morcos, P. P. Nawroth and A. Bierhaus: Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes. Cardiovasc Diabetol 6:9 doi:10.1186/1475-2840-6-9 (2007) (Pubitemid 46443939)
50. M. Neeper, A. M. Schmidt, J. Brett, S. D. Yan, F. Wang, Y. C. Pan, K. Elliston, D. Stren and A. Shaw: Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 267, 14998-15004 (1992)
51. K. Nakamura, S. Yamagishi, H. Adachi, T. Matsui, Y. Kurita-Nakamura, M. Takeuchi, H. Inoue and T. Imaizumi: Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes. Microvasc Res 76, 52-56 (2008)
52. K. Nakamura, S. Yamagishi, H. Adachi, T. Matsui, Y. Kurita-Nakamura, M. Takeuchi, H. Inoue and T. Imaizumi: Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant protein-1 (MCP-1) levels in patients with type 2 diabetes. Diabetes Metab Res Rev 24, 109-114 (2008) (Pubitemid 351284754)
53. K. Nakamura, S. Yamagishi, H. Adachi, Y. Kurita-Nakamura, T. Matsui, T. Yoshida and T. Imaizumi: Serum levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes. Mol Med 13, 185-189 (2007) (Pubitemid 46944961)
54. X. X. Yan, W. H. Peng, L. J. Wang, Q. Zhang, R. Y. Zhang, Q. J. Chen and W. F. Shen: Increased serum HMGB1 level is associated with coronary artery disease in nondiabetic and type 2 diabetic patients. Atherosclerosis 205, 544-548 (2009)
55. J. W. Nin, I. Ferreria, C. G. Schalkwiik, M. H. Prins, N. Chaturvedi, J. H. Fuller and C. D. Stehouwer; EURODIAB Prospective Complications Study Group. Levels of soluble receptor for AGE are cross-sectionally associated with cardiovascular disease in type 1 diabetes, and this association is partially mediated by endothelial and renal dysfunction and by low-grade inflammation: the EURODIAB Prospective Complications Study. Diabetologia 52, 705-714 (2009)
56. J. W. Nin, A. Jorsal, I. Ferreria, C. G. Schalkwiik, M. H. Prins, H. H. Parving, L. Tarnow, P. Rossing and C. D. A. Stehouwer; Higher plasma levels are associated with incident cardiovascular morbility and mortality as well as all-cause mortality in type 1 diabetes: a 12-yr follow-up study. Diabetologia 52(Suppl1), S155 (2009)
57. L. Gu, S. Hagiwara, Q. Fan, M. Tanimoto, M. Kobata, M. Yamashita, T. Nishitani, T. Gohda, Z. Ni, J. Qian, S. Horikoshi and Y. Tomino: Role of receptor for advanced glycation end-products and signalling events in advanced glycation end-product-induced monocyte chemoattractant protein-1 expression in differentiated mouse podocytes. Nephrol Dial Transplant 21, 299-313 (2006) (Pubitemid 43159982)
58. G. Rashid, S. Benchetrit, D. Fishman and J. Bernheim: Effect of advanced glycation end-products on gene expression and synthesis of TNF-alpha and endothelial nitric oxide synthase by endothelial cells. Kidney Int 66, 1099-1106 (2004) (Pubitemid 39121015)
59. G. Cataldegirmen, S. Zehg, N. Feirt, N. Ippagunta, H. Dun, W. Qu, Y. Lu, L. L. Rong, M. A. Hofmann, T. Kislinger, S. I. Pachydaki, D. G. Jenkins, A. Weinberg, J. Lefkowitch, X. Rogiers, S. F. Yan, A. M. Schmidt and J. C. Emond: RAGE limits regeneration after massive liver injury by coordinated suppression of TNF-alpha and NF-kappaB. J Exp Med, 201, 473-484 (2005) (Pubitemid 40229421)
60. F. Galli, S. Benedetti, A. Floridi, F. Canestrari, M. Piroddi, E. Buoncristiani and U. Buoncristiani: Glycoxidation and inflammatory markers in patients on treatment with PMMA-based protein-leaking dialyzers. Kidney Int 67, 750-759 (2005) (Pubitemid 40139870)
61. G. E. Hein, M. Kohler, P. Oelzner, G. Stein and S. Franke: The advanced glycation end product pentosidine correlates to IL-6 and other relevant inflammatory markers in rheumatoid arthritis. Rheumatol Int 26, 137-141 (2005) (Pubitemid 41779823)
62. G. Basta, A. M. Sironi, G. Lazzerini, S. del Turco, E. Buzzigoli, A. Casolaro, A. Natali, E. Ferrannini and A. Gastaldelli: Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein. J Clin Endocrinol Metab 91, 4628-4634 (2006) (Pubitemid 44833448)
63. T. Chavakis, A. Bierhaus, N. Al-Fakhri, D. Schneider, S. Witte, T. Linn, M. Nagashima, J. Morser, B. Arnold, K. T. Preissner and P. P. Nawroth: The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J Exp Med 198, 1507-1515 (2003) (Pubitemid 37467165)
64. E. Devangelio, F. Santilli, G. Formoso, P. Ferroni, L. Bucciarelli, N. Michetti, C. Clissa, G. Ciabattoni, A. Consoli and G. Davì: Soluble RAGE in type 2 diabetes: association with oxidative stress. Free Radic Biol Med 15, 511-518 (2007) (Pubitemid 47058227)
65. N. Grossin, M. P. Wautier, T. Meas, P. J. Guillausseau, P. Massin and J. L. Wautier: Severity of diabetic microvascular complications is associated with a low soluble RAGE level. Diabetes Metab 34, 392-395 (2008)
66. J. M. Forbes, M. E. Cooper, V. Thallas, W. C. Burns, M. C. Thomas, G. C. Brammar, F. Lee, S. L. Grant, L. A. Burrel, G. Jerums and T. M. Osicka: Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. Diabetes 51, 3274-3282 (2002) (Pubitemid 35246974)
67. H. L. Tam, S. W. Shiu, Y. Wong, W. S. Chow, D. J. Betteridge and K. C. Tan: Effects of atorvastatin on serum soluble receptors for advanced glycation end-products in type 2 diabetes. Atherosclerosis (2009)
68. K. C. Tan, W. S. Chow, A. W. Tso, A. Xu, H. F. Tse, R. L. Hoo, D. J. Betteridge and K. S. Lam: Thiazolidinedione increases serum soluble receptor for advanced glycation end-products in type 2 diabetes. Diabetologia 50, 1819-1825 (2007) (Pubitemid 47222871)
69. J. Miura, Y. Yamamoto, M. Osawa, T. Watanabe, H. Yonekura, Y. Uchigata, H. Yamamoto and Y. Iwamoto: Endogenous secretory receptor for advanced glycation endproducts levels are correlated with serum pentosidine and CML in patients with type 1 diabetes. Arterioscler Thromb Vasc Biol 27, 253-254 (2007) (Pubitemid 46360409)
70. T. Gohda, M. Tanimoto, J. Y. Moon, H. Gotoh, T. Aoki, M. Matsumoto, T. Shibata, I. Ohsawa, K. Funabiki and Y. Tomino: Increased serum endogenous secretory receptor for advanced glycation end-product (esRAGE) levels in type 2 diabetic patients with decreased renal function. Diabetes Res Clin Pract 81, 196-201, (2008)
71. M. L. Macrovecchio, C. Giannit, R. N. Dalton, B. Widmer, F. Chiarelit and D. B. Dunger: Reduced endpgenous secretory receptor for advanced glycation end products (esRAGE) in young people with type 1 diabetes developing microalbuminuria. Diabetic Med 26, 815-819 (2009)
72. N. Katakami, M. Matsuhisa, H. Kaneto, T. A. Matsuoka, K. Sakamoto, Y. Nakatani, K. Ohtoshi, R. Hayaishi-Okano, K. Kosugi, M. Hori and Y. Yamazaki: Decreased endogenous secretory advanced glycation end product receptor in type 1 diabetic patients. Diabetes Care 28, 2716-2721 (2005)
73. S. Sakurai, Y. Yamamoto, H. Tamei, H. Matsuki, K. Obata, L. Hui, J. Miura, M. Osawa, Y. Uchigata, Y. Iwamoto, T. Watanabe, H. Yonekura and H. Yamamoto: Development of an ELISA for esRAGE and its application to type 1 diabetic patients. Diabetes Res Clin Pract 73, 158-165 (2006) (Pubitemid 43928158)
74. N. Katakami, M. Matsuhisa, H. Kaneto, T. A. Matsuoka, K. Sakamoto, Y. T. Yasuda, Y. Umayahara, K. Kosugi and Y. Yamazaki: Serum endogenous secretory RAGE level is an independent risk factor for the progression of carotid atherosclerosis in type 1 diabetes. Atherosclerosis 204, 288-292 (2009)
75. N. Katakami, M. Matsuhisa, H. Kaneto and Y. Yamazaki: Serum endogenous secretory RAGE levels are inversely associated with carotid IMT in type 1 diabetic patients. Atherosclerosis 190, 22-23 (2007) (Pubitemid 44908333)
76. H. Koyama, T. Shoji, H. Yokoyama, K. Motoyama, K. Mori, S. Fukumoto, M. Emoto, T. Shoji, H. Tamei, H. Matsuki, S. Sakurai, Y. Yamamoto, H. Yonekura, T. Watanabe, H. Yamamoto and Y. Nishizawa: Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol, 25, 2587-2593 (2005) (Pubitemid 43732283)
77. L. Lu, L. J. Pu, Q. Zhang, L. J. Wang, S. Kang, R. Y. Zhang, Q. J. Chen, J. G. Wang, R. de Caterina and W. F. Shen: Increased glycated albumin and decreased esRAGE levels are related to angiographic severity and extent of coronary artery disease in patients with type 2 diabetes. Atherosclerosis 206, 540-545 (2009)
78. K. M. Choi, H. J. Yoo, H. Y. Kim, K. W. Lee, J. A. Seo, S. G. Kim, N. H. Kim, D. S. Choi and S. H. Basik: Association between endogenous secretory RAGE, inflammatory markers and arterial stiffness. Int J Cardiology 132, 96-101 (2009)
79. P. M. Humpert, G. Papadopoulos, K. Schaefer, Z. Djuric, I. Konrade, M. Morcos, P. P. Nawroth and A. Biehaus: sRAGE and esRAGE are not associated with peripheral or autonomic neuropathy in type 2 diabetes. Horm Metab Res 39, 899-902 (2007)
80. G. Basta, S. Berti, F. Cocci, G. Lazzerini, S. Parri, A. Papa, D. Battaglia, V. Lubrano, S. Del Turco, M. Ravani, A. Rizza, R. De Caterina, P. Marraccini and A. Mazzone: Plasma N-epsilon-(carboxymethyl) lysine levels are associated with the extent of vessel injury after coronary arterial stenting. Coron Artery Dis 19, 299-305 (2008)
81. G. Basta, M. Castagnini, S. Del Turco, M. C. Epistolato, P. Righini, G. M. Sangiorgi, R. De Caterina and P. Tanganelli: High plasma levels of the soluble receptor for advanced glycation endproducts in patients with symptomatic carotid atherosclerosis. Eur J Clin Invest 39, 1065-1072 (2009)
82. Y. Kotyama, Y. Takeishi, T. Niizeki, S. Suzuki, T. Kitahara, T. Sasaki and I. Kubota: Soluble receptor for advanced glycation end products (sRAGE) is a prognostic factor for heart failure. J Card Fail 14, 133-129 (2008)
83. J. D. Christie, C. V. Shah, S. M. Kawut, N. Mangalmurti, D. J. Lederer, J. R. Sonett, V. N. Ahya, S. M. Palmer, K. Wollie, V. Lama, P. D. Shah, A. Shah, A. Weinacker, C. S. Deutschman, B. A. Kohl, E. Demissie, S. Bellamy and L. B. Ware for the Lung Transplant Outcomes Group: Plasma levels of receptor for advanced glycation end products, blood transfusion, and risk of primary graft dysfunction. Am J Respir Cri Care Med 180, 1010-1015 (2009)
84. N. Mahajan, N. Malik, A. Bahl and V. Dhawan: Receptor for advanced glycation end products (RAGE) and its inflammatory ligand EN-RAGE in non-diabetic subjects with pre-mature coronary artery disease. Atherosclerosis 207, 597-602 (2009)
85. C. Falcone, E. Emanuele, A. D'Angelo, M. P. Buzzi, C. Belvito, M. Cuccia and D. Geroldi: Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol 25, 1032-1037 (2005) (Pubitemid 40627851)
86. K. H. Chiang, P. H. Huang, S. S. Huang, T. C. Wu, J. W. Chen and S. J. Lin: Plasma levels of soluble receptor for advanced glycation end products are associated with endothelial function and predict cardiovascular events in nondiabetic patients. Coronary Artery Dis 20, 267-273 (2009)
87. A. Fukami, H. Adachi, S. Yamagishi, T. Matsui, S. Ueda, K. Nakamura, M. Enomoto, M. Otsuka, S. Kumagae, Y. Nanjo, E. Kumagai, E. Esaki, K. Murayama, Y. Hirai and T. Imaizumi: Factors associated with serum high mobility group box 1 (HMGB1) levels in a general population. Metabolism 58, 1688-1693 (2009)
88. A. M. Schmidt, S. D. Yan, S. F. Yan and D. M. Stern: The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 108, 949-955 (2001) (Pubitemid 32946067)
89. A. Soro-Paavonen, A. M. Watson, J. Li, K. Paavonen, A. Koitka, A. C. Calkin, D. Bari, M. T. Coughlan, B. G. Drew, G. I. Lancaster, M. Thomas, J. M. Forbes, P. P. Nawroth, A. Bierhaus, M. E. Cooper and K. A. Jandeleit-Dahm: Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes 57, 2461-2469 (2008)
90. O. Hori, J. Brett, T. Slattery, R. Cao, J. Zhang, J. X. Chen, M. Nagashima, E. R. Lundh, S. Vijay, D. Nitechi, J. Morser, D. Stern and A. M. Schmidt: The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J Biol Chem 270, 25752-25761 (2005)
91. M. Takeuchi, Z. Makita, R. Bucala, T. Suzuki, T. Koiek and Y. Kameda: Immunological evidence that non-carboxymethyllysine advanced glycation end-products are produced from short chain sugars and dicarbonyl compounds in vivo. Mol Med 6, 114-125 (2000)
92. D. Geroldi, C. Falcone, E. Emanuele, A. D'Angelo, M. Calcagnino, M. P. Buzzi, G. A. Scioli and R. Fogari: Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essetial hypertension. J Hypertension 23, 1725-1729 (2005) (Pubitemid 41233433)
93. K. Nakamura, H. Adachi, T. Matsui, Y. Kurita, M. Takeuchi and S. Yamagishi: Independent determinants of soluble form of receptor for advanced glycation end products in elderly hypertensive patients. Metabolism 58, 421-425 (2009)
94. T. Nakamura, E. Sato, N. Fujiwara, Y. Kawagoe, Y. Ueda, T. Suzuki, S. Yamada, M. Takeuchi, K. Fukami, S. Ueda, H. Adachi, T. Matsui, S. Okuda and S. Yamagishi: Positive association of serum levels of advanced glycation end products and high mobility group box-1 with asymmetric dimethylarginine in nondiabetic chronic kidney disease patients. Metabolism 58, 1624-1628 (2009)
95. M. Kalousová, M. Hodková, M. Kazderová, J. Fialová, V. Tesar, S. Dusilová-Sulková and T. Zima: Soluble receptor for advanced glycation end products in patients with decreased renal function. Am J Kidney Dis 47, 406-411 (2006) (Pubitemid 43255173)
96. G. Basta, D. Leonardis, F. Mallamaci, S. Cutrupi, P. Pizzini, L. Gaetano, R. Tripepi, G. Tripepi, R. De Caterina and C. Zoccali: Circulating soluble receptor of advanced glycation end product inversely correlates with atherosclerosis in patients with chronic kidney disease. Kidney Int (2009 in press)
97. S. Gross, R. M. van Ree, L. H. Oterdoom, A. P. de Vries, W. J. van Son, P. E. de Jong, G. J. Navis, M. W. Zuurman, A. Bierhaus, R. O. Gans and S. J. Bakker: Low levels of sRAGE are associated with increased risk for mortality in renal transplant recipients. Transplantation 84, 659-663 (2007) (Pubitemid 47429050)
98. H. Koyama, T. Shoji, S. Fukumoto, K. Shinohara, T. Shoji, M. Emoto, K. Mori, H. Tahara, E. Ishimura, R. Kakiya, T. Tabata, H. Yamamoto and Y. Nishizawa: Low circulating endogenous secretory receptor for AGEs predicts cardiovascular mortality in patients with end-stage renal disease. Arterioscler Thromb Vasc Biol 27, 147-153 (2007) (Pubitemid 46360392)
99. E. Emanuele, A. D'Angelo, C. Tomaino, G. Binetti, R. Ghidoni, P. Politi, L. Bernardi, R. Maletta, A. C. Bruni and D. Geroldi: Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia. Arch Neurol 62, 1734-1736 (2005) (Pubitemid 41626671)
100. R. Ghidoni, L. Benussi, M. Glionna, M. Franzoni, D. Geroldi, E. Emanuele and G. Binetti: Decreased plasma levels of soluble receptor for advanced glycation end products in mild cognitive impairment. J Neural Transm 115, 1047-1050 (2008)
101. D. Geroldi, C. Falcone, P. Minoretti, E. Emanuele, M. Arra and A. D'Angelo: High levels of soluble receptor for advanced glycation end products may be a marker of extreme longevity in humans. J Am Geriatr Soc 54, 1149-1150 (2006) (Pubitemid 43992560)
102. J. Iłzecka: Serum-soluble receptor for advanced glycation end product levels in patients with amyotrophic lateral sclerosis. Acta Neurol Scand 120, 119-122 (2009)
103. Z. Sternberg, B. Weinstock-Guttman, D. Hojnacki, P. Zamboni, R. Zivadinov, K. Chadha, A. Lieberman, L. Kazim, A. Drake, P. Rocco, E. Grazioli and F. Munschauer: Soluble receptor for advanced glycation end products in multiple sclerosis: a potential marker of disease severity. Mult Scler 14, 759-763 (2008)
104. R. Pullerits, H. F. d'Elia, A. Tarkowski and H. Carlsten: The decrease of soluble RAGE levels in rheumatoid arthritis patients following hormone replacement therapy is associated with increased bone mineral density and diminished bone/cartilage turnover: a randomized controlled trial. Rhematology (Oxford) 48, 785-790 (2008)
105. R. Pullerits, M. Bokarewa, L. Dahlberg and A. Tarkowski: Decreased levels of soluble receptor for advanced glycation end products in patients with rheumatoid arthritis indicating deficient inflammatory control. Arthritis Res Ther 7, R817-824 (2005)
106. Y. S. Chen, W. Yan, C. L. Geczy, M. A. Brown and R. Thomas: Serum levels of soluble receptor for advanced glycation end products and of S100 proteins are associated with inflammatory, autoantibody and classical risk markers of joint and vascular damage in rheumatoid arthritis. Arthritis Res Ther 11, R39 (2009)
107. A. Yoshizaki, K. Komura, Y. Iwata, F. Ogawa, T. Hara, E. Muroi, M. Takenaka, K. Shimizu, M. Hasegawa, M. Fujimoto and S. Sato: Clinical significance of serum HMGB-1 and sRAGE levels in systemic sclerosis: association with disease severity. J Clin Immunol 29, 180-189 (2009)
108. H. Wittkowski, K. Hirono, F. Ichida, T. Vogl, F. Ye, X. Yanlin, K. Saito, K. Uese, T. Miyawaki, D. Viemann, J. Roth and D. Foell: Acute Kawasaki disease is associated with reverse regulation of soluble receptor for advance glycation end products and its proinflammatory ligand S100A12. Arthritis Rheum 56, 4174-4181 (2007) (Pubitemid 350262345)
109. C. Stewart, S. Cha, R. M. Caudle, K. Berg and J. Katz: Decreased levels of soluble receptor for advanced glycation end products in patients with primary Sjögren's syndrome. Rheumatol Int 28, 771-776 (2008)
110. T. Nakamura, E. Sato, N. Fujiwara, Y. Kawagoe, T. Suzuki, Y. Ueda, S. Yamada, S. Shoji, M. Takeuchi, S. Ueda, T. Matsui, H. Adachi, T. Matsui, S. Okuda and S. Yamagishi: Circulating levels of advanced glycation end products (AGE) and interleukin-6 (IL-6) are independent determinants of serum asymmetric dimethylarginine (ADMA) levels in patients with septic shock. Pharm Res 60, 515-518 (2009)
111. C. Bopp, S. Hofer, J. Weitz, A. Bierhaus, P. P. Nawroth, E. Martin, M. W. Büchler and M. A. Weigand: sRAGE is elevated in septic patients and associated with patients outcome. J Surg Res 47, 79-83 (2008) (Pubitemid 351626081)
112. Y. Yilmaz, E. Ulukaya, O. O. Gul, M. Arabul, C. B. Gul, O. Atug, A. Y. Oral, S. Aker, E. Dolar: Decreased plasma levels of soluble receptor for advanced glycation endproducts (sRAGE) in patients with nonalcoholic fatty liver disease. Clin Biochem 42, 802-807, (2009)
113. G, Basta, A. I. Corciu, A. Vianello, S. Del Turco, I. Foffa, T. Navarra, D. Chiappino, S. Berti, A. Mazzone: Circulating soluble receptor for advanced glycation end-product levels are decreased in patients with calcific aortic valve stenosis. Atherosclerosis doi:10.1016/j.atherosclerosis.2009.12.029 (2010)
114. P, Tesarová, M. Kalousová, M. Jáchymová, O. Mestek, L. Petruzelka, T. Zima: Receptor for advanced glycation end products (RAGE)-soluble form (sRAGE) and gene polymorphisms in patients with breast cancer. Cancer Invest 25, 720-725 (2007) (Pubitemid 350223177)
115. S, Kobayashi, H. Kubo, T. Suzuki, K. Ishizawa, M. Yamada, M. He, Y. Yamamoto, H. Yamamoto, H. Sasano, H. Sasaki, S. Suzuki: Endogenous secretory receptor for advanced glycation end products in non-small cell lung carcinoma. Am J Respir Crit Care Med 175, 184-189, (2007) (Pubitemid 46115090)
116. A, Germanová, M. Koucký, Z. Hájek, A. Paøízek, T. Zima, Kalousová M: Soluble receptor for advanced glycation end products in physiological and pathological pregnancy. Clin Biochem in press (2010)
117. M. Pertyñska-Marczewska, E. Głowacka, M. Sobczak, K. Cypryk, J. Wilczyñski: Glycation endproducts, soluble receptor for advanced glycation endproducts and cytokines in diabetic and non-diabetic pregnancies. Am J Reprod Immunol 61, 175-182, (2009)